Genetic testing in diverse populations: Are researchers doing enough to get out the correct message?

JAMA

Volumn 298, Issue 24, 2007, Pages 2910-2911

  Huo, Dezheng ^a   Olopade, Olufunmilayo I ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; EDITORIAL; ETHNICITY; FAMILIAL CANCER; GENE MUTATION; GENE REARRANGEMENT; GENETIC SCREENING; HUMAN; ONCOGENE; PREVALENCE; PRIORITY JOURNAL; RACE;

EID: 37549049766     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.24.2910     Document Type: Editorial

References (28)

1. John EM, Miron A, Gong G, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA. 2007;298(24):2869-2876.
2. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: updated 2006. CA Cancer J Clin. 2006;56(3):168-183.
3. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20(11):2701-2712.
4. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295(12):1379-1388.
5. de la Hoya M, Gutiérrez-Enríquez S, Velasco E, et al. Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer. Clin Chem. 2006;52(8):1480-1485.
6. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317- 1325.
7. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351(5):427-437.
8. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365(9473):1769-1778.
9. Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers. Int J Cancer. 2006;118(9):2281-2284.
10. Rebbeck TR, Friebel T, Lynch HT, et al; PROSE Study Group. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(6):1055-1062.
11. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2005;23(30):7491-7496.
12. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616-1622.
13. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609-1615.
14. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers inwomenwith a BRCA1 or BRCA2 mutation. JAMA. 2006;296(2):185-192.
15. Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293(14):1729-1736.
16. Hall M, Olopade OI. Confronting genetic testing disparities: knowledge is power. JAMA. 2005;293(14):1783-1785.
17. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(6):1480-1490.
18. Apicella C, Andrews L, Hodgson SV, et al. Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA). Breast Cancer Res. 2003;5(6):R206-R216.
19. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336(20):1409-1415.
20. Evans DG, Eccles DM, Rahman N, et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004;41(6):474-480.
21. Antoniou AC, Pharoah PD, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002;86(1):76-83.
22. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62(1):145-158.
23. Barcenas CH, Hosain GM, Arun B, et al. Assessing BRCA carrier probabilities in extended families. J Clin Oncol. 2006;24(3):354-360.
24. Parmigiani G, Chen S, Iversen ES Jr, et al. Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med. 2007;147(7):441-450.
25. James PA, Doherty R, Harris M, et al. Optimal selection of individuals for BRCA mutation testing. J Clin Oncol. 2006;24(4):707-715.
26. Suter NM, Ray RM, Hu YW, et al. BRCA1 and BRCA2 mutations in women from Shanghai China. Cancer Epidemiol Biomarkers Prev. 2004;13(2):181-189.
27. Li WF, Hu Z, Rao NY, et al. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality [published online ahead of print September 13, 2007. Breast Cancer Res Treat. doi:10.1007/s10549-007-9708-3. Accessibility verified November 30, 2007.
28. Sng JH, Chang J, Feroze F, et al. The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives. Br J Cancer. 2000;82(3):538-542.